

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.

These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.

Some data have been adjusted to facilitate estimates of standard indicators across countries.

Details of the process for searching, grading and including data, along with their interpretation, are detailed in:

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

For more information on the Reference Group, please go to: www.IDURefGroup.Com

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
1. Needle and syringe programs (NSPs)	5
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
2. Opioid substitution programs (OST)	11
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

Section	Page
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
3. Other Drug Treatment (ODT)	27
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
4. HIV testing and counselling (T&C)	44
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

Section	Page
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
5. Anti-retro-viral (ARV) treatment	47
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
6. Condoms	50
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

China (East and South East Asia)

Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	0.19	0.25	0.31
Year of IDU prevalence estimate	2005		
Reference for IDU prevalence estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	7.96	12.3	19.2
Year of HIV prevalence among IDU estimate	2005		
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age in 2008	945 744 343 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	1 833 000	2 393 000	2 953 000
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	145907	294 339	566 976

1. Needle and syringe programs (NSPs)

NSP 1: Availability of NSPs

Are NSPs available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other NSP indicators
When were NSPs first introduced?	1999
Reference	Knoess, J. (2006). HIV/AIDS and Intravenous Drug Use in Asia: A mapping of existing HIV/AIDS and harm reduction programs, Development Oriented Drug Control Program GTZ Eschborn: 179.
Are needles and syringes available for purchase from pharmacies?	
Most recent year of documentation	
Reference	

NSP 2: Number of NSP sites

Data reported	897 sites 901 NEP sites		
Year of reported data	2008		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO. Wu, Z. (2008). Update of Harm reduction in china		
Adjustments	Figures taken as range		
Final/Adjusted data (to be used as indicator numerator)	897 - 901		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	0.30	0.38	0.49

NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High

NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	> 38000 IDUs access the 901 sites [No information whether this refers to individual clients or occasions of service No information about time period]		
Year of reported data	2008		
Reference	Wu, Z. (2008). Update of Harm reduction in china		
Adjustments	Assumed individual clients accessing NSP in 2008		
Final/Adjusted data (to be used as indicator numerator)	> 38000		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	1.3	1.6	2.1

NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	> 38000 IDUs access the 901 sites [No information whether this refers to individual clients or occasions of service No information about time period]		
Year of reported data	2008		
Reference	Wu, Z. (2008). Update of Harm reduction in china		
Adjustments	Assumed count is occasions of service		
Final/Adjusted data (to be used as indicator numerator)	> 38000		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	0.01	0.02	0.02

NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

Data reported	1 173 764 needles distributed 152 715 768 syringes distributed		
Year of reported data	2008		
Reference	National working group on community-based MMT for Opium dependents (2009). Scaling-up the methadone maintenance treatment program in China. WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments	Figures taken as range		
Final/Adjusted data (to be used as indicator numerator)	1 173 764 - 152 715 768		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU	Low	Mid	High
	0.40	32.2	83.31

NSP: All documents reviewed

- Asia Regional HIV/AIDS Project (2007). Evaluation of effective approaches (EAPs) in China (Guangxi and Yunnan).
- Asia Regional HIV/AIDS Project (2007). Independent completion report.
- AVERT. (2008). "Needle exchanges." Retrieved 30 November, 2008, from <http://www.avert.org/needle-exchange.htm>
- Brown, T. (2006). HIV/AIDS in Hong Kong: living on the edge. Kowloon, East/West Center: 38.
- Cohen, J. (2004). "HIV/AIDS in China. Changing course to break the HIV-heroin connection." *Science* 304(5676): 1434-5.
- Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.
- Gill, B. and S. Okie (2007). "China and HIV - a window of opportunity.[erratum appears in *N Engl J Med.* 2007 Aug 23;357(8):835]." *New England Journal of Medicine* 356(18): 1801-5.
- Hammett, T. M., N. A. Bartlett, et al. (2005). "Law enforcement influences on HIV prevention for injection drug users: Observations from a cross-border project in China and Vietnam." *International Journal of Drug Policy* 16(4): 235-245.
- Hammett, T. M., Z. Wu, et al. (2008). "'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam." *Addiction* 103(1): 137-45.
- HIV/AIDS Asia Regional Program (HAARP). (2009). "China Country Flexible Program " Retrieved 19 October, 2009, from <http://www.haarp-online.org/www/html/296-china-country-flexible-program.asp?intSiteID=1>.
- International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.
- International Harm Reduction Development Program (2008). Harm reduction developments 2008. New York.
- Jianhua, L. Strengthening the role of law enforcement in China's HIV response.
- Knoess, J. (2006). HIV/AIDS and Intravenous Drug Use in Asia: A mapping of existing HIV/AIDS and harm reduction programs, Development Oriented Drug Control Program GTZ Eschborn: 179.
- Knoess, J. (2006). HIV/AIDS and Intravenous Drug Use in Asia: A mapping of existing HIV/AIDS and Harm Reduction Programs, Development Oriented Drug Control Program.
- Lau, J. T. F., L. Zhang, et al. (2008). "Changes in the prevalence of HIV-related behaviors and perceptions among 1832 injecting drug users in Sichuan, China." *Sexually Transmitted Diseases* 35(4): 325-35.
- Liu, B., S. G. Sullivan, et al. (2007). "An evaluation of needle exchange programmes in China." *AIDS* 21 Suppl 8: S123-8.
- Liu, Z., Z. Lian, et al. (2006). "Drug use and HIV/AIDS in China." *Drug & Alcohol Review* 25(2): 173-5.
- Mesquita, F., D. Jacka, et al. (2008). "Accelerating harm reduction interventions to confront the HIV epidemic in the Western Pacific and Asia: the role of WHO (WPRO)." *Harm Reduction Journal* 5(1): 26.
- Mingjian, N., W. J. Ping, et al. Expanded needle and syringe exchange programs in Xinjiang Uyghur Autonomous Region.
- Monitoring AIDS Pandemic (MAP) Network (2004). AIDS in Asia: face the facts. A comprehensive analysis of the AIDS epidemics in Asia, Monitoring AIDS Pandemic (MAP) Network.
- Monitoring AIDS Pandemic Network (2005). MAP Report 2005: Drug injection and HIV/AIDS in Asia.
- National working group on community-based MMT for Opium dependents (2009). Scaling-up the methadone maintenance treatment program in
- Qian, H., J. Schumacher, et al. (2006). "Injection drug use and HIV/AIDS in China: Review of current situation, prevention and policy implications." *Harm Reduct J* 3(4): 1-26.
- Reid, G., M. L. Devaney, et al. (2008). "Harm reduction programmes in the Asia-Pacific Region." *Drug & Alcohol Review* 27(1): 95-8.
- Reid, G., M. L. Devaney, et al. (2008). "Harm reduction programmes in the Asia-Pacific Region." *Drug and Alcohol Review* 27(1): 95-98.
- Sullivan, S. G. and Z. Wu (2007). "Rapid scale up of harm reduction in China." *International Journal of Drug Policy* 18(2): 118-28.

NSP: All documents reviewed

UNAIDS (2004). UNAIDS at country level progress report, UNAIDS.

UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.

UNAIDS (2009). Drug use and HIV in China.

UNODC regional centre for East Asia and the Pacific (2006). HIV/AIDS and custodial settings in South East Asia - An exploratory review into the issues of HIV/AIDS and custodial settings in Cambodia, China, Lao PDR, Myanmar, Thailand and Viet Nam. Thailand.

USAID (2007). Understanding service utilization practices of most-at-risk populations accessing a minimum package of HIV/AIDS prevention interventions (DRAFT - Not for circulation).

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

Wu, Z. (2008). Update of Harm reduction in china

Wu, Z., S. G. Sullivan, et al. (2007). "Evolution of China's response to HIV/AIDS.[see comment]." Lancet 369(9562): 679-90.

2. Opioid substitution treatment (OST)

OST 1: Availability of opioid substitution treatment (OST)

Are any forms of agonist OST available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was agonist OST first available?	2004
Reference	Jianhua, L., L. Peikai, et al. A non-chochrane review to opioid dependence treatment in China. Kunming, Yunnan.

OST 2: Availability of methadone maintenance treatment (MMT)

Is MMT available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was MMT first available?	2004
Reference	Jianhua, L., L. Peikai, et al. A non-chochrane review to opioid dependence treatment in China. Kunming, Yunnan.

OST 3: Availability of buprenorphine maintenance treatment (BMT)

Is BMT available?	Yes
Comments	
Most recent year of documentation	2009
Reference	Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009.
When was BMT first available?	2008
Reference	Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009.

OST 4: Availability of other forms of agonist OST

Are other forms of OST available?	
Comments	
Most recent year of documentation	
Reference	
When were other forms of OST first available?	
Reference	

OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	54-100mg/day
Comments	Maintenance dosage is about 80-100mg/day 54 mg in Hong Kong
Year	2006 2009
Reference	Jianhua, L., L. Peikai, et al. A non-cochrane review to opioid dependence treatment in China. Kunming, Yunnan. World Health Organisation (2009). Global health ATLAS data.
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	
Comments	
Year	
Reference	
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

OST 7: Total number of all sites providing OST

Data reported	621 sites (694 MMT sites 2 BMT sites)		
Year of reported data	2008 2009 2005		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO. Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Response to "China - UN Reference Group - Final Data Check". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 22 Oct 2009. Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009. Farrell, M., W. Ling, et al. (2005). Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Evidence for action technical papers, World Health Organization (WHO).		
Adjustments	Figures taken as range		
Final/Adjusted data (to be used as indicator numerator)	621 - 696		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	954 436 499 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 850 000	2 415 000	2 980 000
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	0.21	0.40	0.38

OST 8: Number of sites providing MMT

Data reported	647 MMT clinics in 24 provinces 26 MMT vans in 9 provinces 21 MMT sites in Hong Kong		
Year of reported data	2009 2005		
Reference	Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Response to "China - UN Reference Group - Final Data Check". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 22 Oct 2009. Farrell, M., W. Ling, et al. (2005). Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Evidence for action technical papers, World Health Organization (WHO).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	694		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	954 436 499 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 850 000	2 415 000	2 980 000
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	0.23	0.29	0.38

OST 9: Number of sites providing BMT

Data reported	Pilot project in Xinjiang and Guangxi (2008 - 2010)		
Year of reported data	2009		
Reference	Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	2		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	954 436 499 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 850 000	2 415 000	2 980 000
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	0.00	0.00	0.00

OST 10: Number of sites providing other forms of agonist OST

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High

OST 11: Number of all clients in any OST at a single point in time

Data reported	93 773 clients in MMT (Dec 2008) 1200 clients in BMT (pilot) 8622 - 9095 clients registered with the methadone clinics as at the end of the year in Hong Kong (not included in reported count of OST clients for China)		
Year of reported data	2008 2009 2005		
Reference	National working group on community-based MMT for Opium dependents (2009). Scaling-up the methadone maintenance treatment program in China.; Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009. World Health Organisation (2009). Global health ATLAS data. Hong Kong Department of Health (2005/2006). Department of Health Annual Report.		
Adjustments	Assumed mutually exclusive Assuming counts correct for same time period Assumed enrolment at a census date Hong Kong data added to China data		
Final/Adjusted data (to be used as indicator numerator)	103 595 - 10 4068		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	954 436 499 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 850 000	2 415 000	2 980 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs	Low	Mid	High
	3.48	4.30	5.63

OST 12: Number of all clients in MMT at a single point in time

Data reported	93 773 clients in MMT (Dec 2008) 8622 - 9095 clients registered with the methadone clinics as at the end of the year in Hong Kong (not included in reported count of OST clients for China)		
Year of reported data	2008 2009 2005		
Reference	National working group on community-based MMT for Opium dependents (2009). Scaling-up the methadone maintenance treatment program in China.; Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009. World Health Organisation (2009). Global health ATLAS data. Hong Kong Department of Health (2005/2006). Department of Health Annual Report.		
Adjustments	Assumed enrolment at a census date		
Final/Adjusted data (to be used as indicator numerator)	102 395 - 102 868		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	954 436 499 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 850 000	2 415 000	2 980 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs	Low	Mid	High
	3.44	4.25	5.56

OST 13: Number of all clients in BMT at a single point in time

Data reported	1200 clients in BMT (pilot)		
Year of reported data	2008		
Reference	Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009.		
Adjustments	Assumed single point in time		
Final/Adjusted data (to be used as indicator numerator)	1200		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	0.04	0.05	0.07

OST 14: Number of all clients in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High

OST 15: Number of IDUs in any OST at a single point in time

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2008 2005		
Reference	National working group on community-based MMT for Opium dependents (2009). Scaling-up the methadone maintenance treatment program in China. Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009. Hong Kong Department of Health (2005/2006). Department of Health Annual Report.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Percentage of IDUs in OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST 16: Number of IDUs in MMT at a single point in time

Data reported	MMT available but number of IDUs not known		
Year of reported data	2008 2005		
Reference	National working group on community-based MMT for Opium dependents (2009). Scaling-up the methadone maintenance treatment program in China. Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009. Hong Kong Department of Health (2005/2006). Department of Health Annual Report.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Percentage of IDUs in MMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 17: Number of IDUs in BMT at a single point in time

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2008		
Reference	Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High

OST 19: Number of all clients receiving any OST in a 12 month period

Data reported	OST available but number of clients on OST not known		
Year of reported data	2008		
	2009		
	2005		
Reference	National working group on community-based MMT for Opium dependents (2009). Scaling-up the methadone maintenance treatment program in China.; Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009.		
	World Health Organisation (2009). Global health ATLAS data.		
	Hong Kong Department of Health (2005/2006). Department of Health Annual Report.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	954 436 499 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 850 000	2 415 000	2 980 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 20: Number of all clients receiving MMT in a 12 month period

Data reported	MMT available but number of clients not known		
Year of reported data	2008 2009 2005		
Reference	National working group on community-based MMT for Opium dependents (2009). Scaling-up the methadone maintenance treatment program in China.; Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009. World Health Organisation (2009). Global health ATLAS data. Hong Kong Department of Health (2005/2006). Department of Health Annual Report.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	954 436 499 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 850 000	2 415 000	2 980 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 21: Number of all clients receiving BMT in a 12 month period

Data reported	BMT available but number of clients not known		
Year of reported data	2008		
Reference	Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 22: Number of all clients receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High

OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2008 2005		
Reference	National working group on community-based MMT for Opium dependents (2009). Scaling-up the methadone maintenance treatment program in China. Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009. Hong Kong Department of Health (2005/2006). Department of Health Annual Report.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	MMT available but number of IDUs not known		
Year of reported data	2008 2005		
Reference	National working group on community-based MMT for Opium dependents (2009). Scaling-up the methadone maintenance treatment program in China. Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009. Hong Kong Department of Health (2005/2006). Department of Health Annual Report.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 25: Number of IDUs receiving BMT in a 12 month period

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2008		
Reference	Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 26: Number of IDUs receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High

OST: All documents reviewed

- (2008). "Southwest China opens methadone clinics in border areas to prevent spread of HIV." *AIDS Reader* 18(3): C2.
- (2008). Remarks by Mr. Gary Lewis at the Opening Ceremony of the First Asian Consultation on the Prevention of HIV related to Drug Use, Goa, India 28-31 January 2008. First Asian Consultation. Goa, UNODC.
- Asian Harm Reduction Network (AHRN) (2004). Scaling up provision of anti-retrovirals to injecting drug users and non-injecting drug users in Asia: World Health Organization "3 x 5" initiative, Asian Harm Reduction Network (AHRN).
- Atmosukarto, I. I. (2008). Indonesia's experience pushing harm reduction forward.
- Brown, T. (2006). HIV/AIDS in Hong Kong: living on the edge. Kowloon, East/West Center: 38.
- Burrows, D. (2006). "Advocacy and coverage of needle exchange programs: results of a comparative study of harm reduction programs in Brazil, Bangladesh, Belarus, Ukraine, Russian Federation, and China." *Cadernos de Saude Publica* 22(4): 871-9.
- Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.
- Chatterjee, P. (2008). "The Methadone Fix." *Bulletin of the World Health Organization* 86(3): 164-165.
- Chengzheng, Z., L. Zhimin, et al. (2004). "Drug Abuse in China." *Annals of the New York Academy of Sciences* 1025(1 Current Status of Drug Dependence/Abuse Studies: Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity): 439-445.
- Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.
- Farrell, M., W. Ling, et al. (2005). Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Evidence for action technical papers, World Health Organization (WHO).
- Gill, B. and S. Okie (2007). "China and HIV - a window of opportunity.[erratum appears in *N Engl J Med.* 2007 Aug 23;357(8):835]." *New England Journal of Medicine* 356(18): 1801-5.
- Hammett, T. M., Z. Wu, et al. (2008). "'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam." *Addiction* 103(1): 137-45.
- HIV/AIDS Asia Regional Program (HAARP) (2006). Program design document - Final.
- Hong Kong Department of Health (2005/2006). Department of Health Annual Report.
- International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.
- International Harm Reduction Development Program (2008). Harm reduction developments 2008. New York.
- International Narcotics Control Board (2008). Report of the International Narcotics Control Board for 2007. Vienna.
- Jianhua, L. (Deputy Director), Yunnan Institute for Drug Abuse. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - China". Kunming, China, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 7 May
- Jianhua, L. Strengthening the role of law enforcement in China's HIV response.
- Jianhua, L., L. Peikai, et al. A non-chochrane review to opioid dependence treatment in China. Kunming, Yunnan.
- Knoess, J. (2006). HIV/AIDS and Intravenous Drug Use in Asia: A mapping of existing HIV/AIDS and harm reduction programs, Development Oriented Drug Control Program GTZ Eschborn: 179.
- Lau, J. T. F., L. Zhang, et al. (2008). "Changes in the prevalence of HIV-related behaviors and perceptions among 1832 injecting drug users in Sichuan, China." *Sexually Transmitted Diseases* 35(4): 325-35.
- Liu, Z., Z. Lian, et al. (2006). "Drug use and HIV/AIDS in China." *Drug & Alcohol Review* 25(2): 173-5.
- Mesquita, F., D. Jacka, et al. (2008). "Accelerating harm reduction interventions to confront the HIV epidemic in the Western Pacific and Asia: the role of WHO (WPRO)." *Harm Reduction Journal* 5(1): 26.
- Monitoring AIDS Pandemic Network (2005). MAP Report 2005: Drug injection and HIV/AIDS in Asia.
- National MMT Work Team (2008). MMT development in China.

OST: All documents reviewed

- National working group on community-based MMT for Opium dependents (2009). Scaling-up the methadone maintenance treatment program in
- Pang, T. T. and S. S. Lee (2008). "Measuring the geographic coverage of methadone maintenance programme in Hong Kong by using geographic information system (GIS)." *International Journal of Health Geographics* 7(1): 5.
- Population Services International (2007). IDU Program - Yunnan Province.
- Qian, H., J. Schumacher, et al. (2006). "Injection drug use and HIV/AIDS in China: Review of current situation, prevention and policy implications." *Harm Reduct J* 3(4): 1-26.
- Reid, G., M. L. Devaney, et al. (2008). "Harm reduction programmes in the Asia-Pacific Region." *Drug & Alcohol Review* 27(1): 95-8.
- Reid, G., M. L. Devaney, et al. (2008). "Harm reduction programmes in the Asia-Pacific Region." *Drug and Alcohol Review* 27(1): 95-98.
- Sullivan, S. G. and Z. Wu (2007). "Rapid scale up of harm reduction in China." *International Journal of Drug Policy* 18(2): 118-28.
- Tang, Y.-L., D. Zhao, et al. (2006). "Opiate addiction in China: current situation and treatments." *Addiction* 101(5): 657-65.
- UNAIDS (2004). UNAIDS at country level progress report, UNAIDS.
- UNAIDS (2006). High coverage sites - HIV prevention among injecting drug users in transitional and developing countries. UNAIDS best practice collection. Geneva.
- UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.
- UNAIDS (2009). Drug use and HIV in China.
- UNODC Regional Centre for East Asia and the Pacific (2006). HIV/AIDS and custodial settings in South East Asia - An exploratory review into the issues of HIV/AIDS and custodial settings in Cambodia, China, Lao PDR, Myanmar, Thailand and Viet Nam. Thailand.
- USAID (2007). Understanding service utilization practices of most-at-risk populations accessing a minimum package of HIV/AIDS prevention interventions (DRAFT - Not for circulation).
- World Health Organization (WHO) Regional Office for the Western Pacific (2006). Fourth partners meeting on HIV prevention and care with injecting drug users. Manila, Phillipines, World Health Organisation (WHO) Regional Office for the Western Pacific.
- Wu, Z. (2008). Update of Harm reduction in china
- Wu, Z., S. G. Sullivan, et al. (2007). "Evolution of China's response to HIV/AIDS.[see comment]." *Lancet* 369(9562): 679-90.

3. Other drug treatment (ODT)**ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

Is detoxification available?	Yes		
Number of sites - data reported	200 voluntary detox clinics Detox available at 21 MMT sites in Hong Kong		
Year of reported data	2007 2005		
Reference	Chengzheng, Z., L. Zhimin, et al. (2004). "Drug Abuse in China." Annals of the New York Academy of Sciences 1025(1 Current Status of Drug Dependence/Abuse Studies: Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity): 439-445. Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS. Farrell, M., W. Ling, et al. (2005). Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Evidence for action technical papers, World Health Organization (WHO). Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	221		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	936 103 583 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 814 500	2 368 500	2 923 000
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High
	0.08	0.09	0.12

ODT 1.2: Number of IDUs receiving detoxification

Data reported	Detoxification available but number not known		
Year of reported data	2007 2005		
Reference	<p>Chengzheng, Z., L. Zhimin, et al. (2004). "Drug Abuse in China." Annals of the New York Academy of Sciences 1025(1 Current Status of Drug Dependence/Abuse Studies: Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity): 439-445.</p> <p>Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.</p> <p>Farrell, M., W. Ling, et al. (2005). Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Evidence for action technical papers, World Health Organization (WHO).</p> <p>Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.</p>		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	936 103 583 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 814 500	2 368 500	2 923 000
INDICATOR: Percentage of IDUs in detoxification in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in detoxification at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

Data reported	Detoxification available but number not known		
Year of reported data	2007 2005		
Reference	<p>Chengzheng, Z., L. Zhimin, et al. (2004). "Drug Abuse in China." Annals of the New York Academy of Sciences 1025(1 Current Status of Drug Dependence/Abuse Studies: Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity): 439-445.</p> <p>Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.</p> <p>Farrell, M., W. Ling, et al. (2005). Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Evidence for action technical papers, World Health Organization (WHO).</p> <p>Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.</p>		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	936 103 583 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 814 500	2 368 500	2 923 000
INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 2 - Residential rehabilitation

ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?			
Number of sites - data reported	Residential rehabilitation present in Hong Kong but number not known		
Year of reported data	2005		
Reference	Farrell, M., W. Ling, et al. (2005). Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Evidence for action technical papers, World Health Organization (WHO). Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data	913 461 218 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 770 500	2 311 500	2 852 500
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High

ODT 2.2: Number of IDUs in residential rehabilitation

Data reported	Residential rehabilitation present in Hong Kong but number not known		
Year of reported data	2005		
Reference	Farrell, M., W. Ling, et al. (2005). Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Evidence for action technical papers, World Health Organization (WHO). Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	913 461 218 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 770 500	2 311 500	2 852 500
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High
	0.07	0.09	0.11

ODT 2.3: Number of all clients in residential rehabilitation

Data reported	Residential rehabilitation present in Hong Kong but number not known		
Year of reported data	2005		
Reference	Farrell, M., W. Ling, et al. (2005). Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Evidence for action technical papers, World Health Organization (WHO). Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	913 461 218 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 770 500	2 311 500	2 852 500
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High

ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?	yes		
Number of sites - data reported	20 sites offering psychosocial support and counselling in Hong Kong		
Year of reported data	2006		
Reference	Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	20 (SN)		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	920 763 312 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 784 500	2 330 000	2 875 000
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High
	0.01	0.01	0.01

ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychosocial support and counselling present in Hong Kong but number not known		
Year of reported data	2006		
Reference	Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	920 763 312 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 784 500	2 330 000	2 875 000
INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time	Low	Mid	High

ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychosocial support and counselling present in Hong Kong but number not known		
Year of reported data	2006		
Reference	Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	920 763 312 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 784 500	2 330 000	2 875 000
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs	Low	Mid	High

ODT 4 - Peer-based support groups

ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	11 NA meetings per week in China 3 NA meetings per week in Hong Kong		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	14		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	0.00	0.01	0.01

ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 4.3: Number of all clients in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs	Low	Mid	High
	NK	null	null

ODT 5 - Drug treatment (treatment type not specified)

ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High

ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High

ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High

ODT 6 - Drug treatment in prisons

ODT 6.1: Number of prison drug treatment sites

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported	Approximately 700 compulsory detoxification settings and approximately 300 re-education through a labour camps in China Compulsory Drug Addiction Treatment Centres (DATC), operated by the Correctional Services Department, to which drug users are sentenced by a criminal court in Hong Kong		
Year of reported data	2007 2002		
Reference	Chengzheng, Z., L. Zhimin, et al. (2004). "Drug Abuse in China." Annals of the New York Academy of Sciences 1025(1 Current Status of Drug Dependence/Abuse Studies: Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity): 439-445. Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	1000		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	936 103 583 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 814 500	2 368 500	2 923 000
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High
	0.34	0.42	0.55

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported	Compulsory drug treatment present but number of IDUs not available		
Year of reported data	2007 2002		
Reference	Chengzheng, Z., L. Zhimin, et al. (2004). "Drug Abuse in China." Annals of the New York Academy of Sciences 1025(1 Current Status of Drug Dependence/Abuse Studies: Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity): 439-445. Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	936 103 583 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 814 500	2 368 500	2 923 000
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported	240000 drug users in compulsory detoxification centres, 60000 drug users in indoctrination-through-labour centres Compulsory Drug Addiction Treatment Centres (DATC), operated by the Correctional Services Department, to which drug users are sentenced by a criminal court but number not known in Hong Kong		
Year of reported data	2007 2002		
Reference	Chengzheng, Z., L. Zhimin, et al. (2004). "Drug Abuse in China." Annals of the New York Academy of Sciences 1025(1 Current Status of Drug Dependence/Abuse Studies: Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity): 439-445. Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	300 000		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	936 103 583 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 814 500	2 368 500	2 923 000
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
	0.10	0.13	0.17
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	

ODT: All documents reviewed

ACCORD (2006). China. Country Summary.

ASEAN and China Cooperative Operations in Response to Dangerous Drugs (ACCORD) (2005). Towards a drug free ASEAN and China 2015: Assessing ACCORD progress 2000-2005. UNODC Regional Centre for East Asia and the Pacific and Association of Southeast Asian Nations.

Asia Regional HIV/AIDS Project (2007). Evaluation of effective approaches (EAPs) in China (Guangxi and Yunnan).

Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .

Burrows, D. (2006). "Advocacy and coverage of needle exchange programs: results of a comparative study of harm reduction programs in Brazil, Bangladesh, Belarus, Ukraine, Russian Federation, and China." *Cadernos de Saude Publica* 22(4): 871-9.

Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.

Chengzheng, Z., L. Zhimin, et al. (2004). "Drug Abuse in China." *Annals of the New York Academy of Sciences* 1025(1 Current Status of Drug Dependence/Abuse Studies: Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity): 439-445.

Cohen, J. (2004). "HIV/AIDS in China. Changing course to break the HIV-heroin connection." *Science* 304(5676): 1434-5.

Des Jarlais, D., T. Perlis, et al. (2006). "Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II." *BMC Public Health* 6(1): 54.

Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.

Farrell, M., W. Ling, et al. (2005). Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Evidence for action technical papers, World Health Organization (WHO).

Hammett, T. M., N. A. Bartlett, et al. (2005). "Law enforcement influences on HIV prevention for injection drug users: Observations from a cross-border project in China and Vietnam." *International Journal of Drug Policy* 16(4): 235-245.

Hammett, T. M., Z. Wu, et al. (2008). "'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam." *Addiction* 103(1): 137-45.

International Harm Reduction Association (2008). Harm Reduction and Human Rights: The Global Response to Injection-Driven HIV Epidemics:

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

Jianhua, L. Strengthening the role of law enforcement in China's HIV response.

Lu, L., D. Zhao, et al. (2008). "Methadone maintenance treatment of heroin abuse in China." *American Journal of Drug & Alcohol Abuse* 34(2): 127-

Monitoring AIDS Pandemic (MAP) Network (2004). AIDS in Asia: face the facts. A comprehensive analysis of the AIDS epidemics in Asia, Monitoring AIDS Pandemic (MAP) Network.

Population Services International (2007). IDU Program - Yunnan Province.

Qian, H., J. Schumacher, et al. (2006). "Injection drug use and HIV/AIDS in China: Review of current situation, prevention and policy implications." *Harm Reduct J* 3(4): 1-26.

Sullivan, S. G. and Z. Wu (2007). "Rapid scale up of harm reduction in China." *International Journal of Drug Policy* 18(2): 118-28.

Tang, Y.-L., D. Zhao, et al. (2006). "Opiate addiction in China: current situation and treatments." *Addiction* 101(5): 657-65.

UNAIDS (2006). High coverage sites - HIV prevention among injecting drug users in transitional and developing countries. UNAIDS best practice collection. Geneva.

UNODC Regional Centre for East Asia and the Pacific (2006). HIV/AIDS and custodial settings in South East Asia - An exploratory review into the issues of HIV/AIDS and custodial settings in Cambodia, China, Lao PDR, Myanmar, Thailand and Viet Nam. Thailand.

USAID (2007). Understanding service utilization practices of most-at-risk populations accessing a minimum package of HIV/AIDS prevention interventions (DRAFT - Not for circulation).

4. HIV testing and counselling (T&C)**T&C 1: Availability of HIV T&C**

Is T&C available?	Yes
Most recent year of data	2008
Reference	See references for other VCT indicators

T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High

T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported	3037 free VCT sites		
Year of reported data	2007		
Reference	Sullivan, S. G. and Z. Wu (2007). "Rapid scale up of harm reduction in China." International Journal of Drug Policy 18(2): 118-28.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	3037		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	936 103 583 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 814 500	2 368 500	2 923 000
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	1.04	1.28	1.67

T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported	26018 drug users sought VCT services from Jan - June 2006		
Year of reported data	2006		
Reference	Sullivan, S. G. and Z. Wu (2007). "Rapid scale up of harm reduction in China." International Journal of Drug Policy 18(2): 118-28.		
Adjustments	Assumed all drug users seeking VCT are IDUs Assumed rate of access constant over 12 months		
Final/Adjusted data (to be used as indicator numerator)	52 036		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	920 763 312 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 784 500	2 330 000	2 875 000
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High
	1.81	2.23	2.92

T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	2007
Reference	UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362. WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.
Data reported for both male and female IDUs	41% IDUs received an HIV test in the last 12 months and know their results 42% IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	41% - 42%
Data reported for male IDUs	40% male IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	40.00%
Data reported for female IDUs	45% female IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	45.00%

T&C: All documents reviewed

AVERT. (2008, 10 March 2009). "HIV and AIDS in Asia." Retrieved 30 Nov 2008, 2008, from <<http://www.avert.org/aids-asia.htm>>

Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.

Country coordinating mechanism - P R China (2008). Reaching vulnerable migrants with HIV/AIDS prevention and care services in seven provinces in China. Beijing: 85.

Family Health International (2007). Final Report for the Implementing AIDS Prevention and Care (IMPACT) Project in China. Arlington VA: 34.

Lau, J. T. F., L. Zhang, et al. (2008). "Changes in the prevalence of HIV-related behaviors and perceptions among 1832 injecting drug users in Sichuan, China." *Sexually Transmitted Diseases* 35(4): 325-35.

Ma, W., R. Detels, et al. (2007). "Acceptance of and barriers to voluntary HIV counselling and testing among adults in Guizhou province, China." *AIDS* 21 Suppl 8: S129-35.

Mesquita, F., D. Jacka, et al. (2008). "Accelerating harm reduction interventions to confront the HIV epidemic in the Western Pacific and Asia: the role of WHO (WPRO)." *Harm Reduction Journal* 5(1): 26.

Population Services International (2007). IDU Program - Yunnan Province.

Sullivan, S. G. and Z. Wu (2007). "Rapid scale up of harm reduction in China." *International Journal of Drug Policy* 18(2): 118-28.

UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.

USAID (2007). Understanding service utilization practices of most-at-risk populations accessing a minimum package of HIV/AIDS prevention interventions (DRAFT - Not for circulation).

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

Wu, Z. (2008). Update of Harm reduction in china

Wu, Z., S. G. Sullivan, et al. (2007). "Evolution of China's response to HIV/AIDS.[see comment]." *Lancet* 369(9562): 679-90.

5. Anti-retro-viral (ARV) treatment**ARV 1: Number of sites providing ARV treatment**

Data reported	1574 sites		
Year of reported data	2008		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments	Assumed data from 2008		
Final/Adjusted data (to be used as indicator numerator)	1574		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
HIV among IDU prevalence estimate (%)	Low	Mid	High
	7.96	12.30	19.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)	Low	Mid	High
	145907	294 339	566 976
INDICATOR: Number of ARV treatment sites per 1000 IDUs	Low	Mid	High
	0.53	0.66	0.86
INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV	Low	Mid	High
	2.78	5.35	10.79

ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported	9300 IDUs on ART		
Year of reported data	2009		
Reference	(Unpublished). Combating the Twin Epidemics of HIV/AIDS and Drug Addiction: Opportunities for Progress and Gaps in Scale - A Report of the CSIS Task Force on HIV/AIDS, Center for Strategic and International Studies.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	9300		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	954 436 499 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 850 000	2 415 000	2 980 000
HIV among IDU prevalence estimate (%)	Low	Mid	High
	7.96	12.30	19.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	147 260	297 045	572 160
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High
	1.63	3.13	6.32

ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	
Year of reported data	
Reference	

ARV: All documents reviewed

Aceijas, C., E. Oppenheimer, et al. (2006). "Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5")." *Addiction* 101(9): 1246-53.

Asian Harm Reduction Network (AHRN) (2004). *Scaling up provision of anti-retrovirals to injecting rug users and non-injecting drug users in Asia: World Health Organization "3 x 5" initiative, Asian Harm Reduction Network (AHRN).*

Country Coordinating Mechanism People's Republic of China (2007). *Proposal form - round 7: China. Beijing: 107.*

Family Health International (2007). *Final Report for the Implementing AIDS Prevention and Care (IMPACT) Project in China. Arlington VA: 34.*

Farrell, M., W. Ling, et al. (2005). *Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Evidence for action technical papers, World Health Organization (WHO).*

International Harm Reduction Association (2008). *Harm Reduction and Human Rights: The Global Response to Injection-Driven HIV Epidemics:*

International Harm Reduction Association, Human Rights Watch, et al. (2008). *Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy.*

Mesquita, F., D. Jacka, et al. (2008). "Accelerating harm reduction interventions to confront the HIV epidemic in the Western Pacific and Asia: the role of WHO (WPRO)." *Harm Reduction Journal* 5(1): 26.

Mingjian, N., W. J. Ping, et al. *Expanded needle and syringe exchange programs in Xinjiang Uyghur Autonomous Region.*

Office of the State Council Working Committee on AIDS - China (2005). *Progress on implementing UNGASS declaration of committment in China*

Sullivan, S. G. and Z. Wu (2007). "Rapid scale up of harm reduction in China." *International Journal of Drug Policy* 18(2): 118-28.

WHO, UNAIDS., et al. (2009). *Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.*

Wu, Z. (2008). *Update of Harm reduction in china*

Wu, Z., S. G. Sullivan, et al. (2007). "Evolution of China's response to HIV/AIDS.[see comment]." *Lancet* 369(9562): 679-90.

6. Condoms

Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	Yes
Comments	
Year	2007
Reference	Sullivan, S. G. and Z. Wu (2007). "Rapid scale up of harm reduction in China." International Journal of Drug Policy 18(2): 118-28. USAID (2007). Understanding service utilization practices of most-at-risk populations accessing a minimum package of HIV/AIDS prevention interventions (DRAFT - Not for circulation).

Condoms 2: Number of sites distributing condoms to IDUs

Data reported	NSP sites in Guangxi and Sichuan distribute condoms 901 NSP sites in country		
Year of reported data	2008		
Reference	Sullivan, S. G. and Z. Wu (2007). "Rapid scale up of harm reduction in China." International Journal of Drug Policy 18(2): 118-28. Wu, Z. (2008). Update of Harm reduction in china		
Adjustments	Assumed all NSPs nationally provide condoms		
Final/Adjusted data (to be used as indicator numerator)	901		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	0.31	0.38	0.49

Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High

Condoms 4: Number of condoms distributed to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2008		
Reference	Sullivan, S. G. and Z. Wu (2007). "Rapid scale up of harm reduction in China." International Journal of Drug Policy 18(2): 118-28. Wu, Z. (2008). Update of Harm reduction in china		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.19	0.25	0.31
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	945 744 343 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 833 000	2 393 000	2 953 000
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	NK	NK	NK

Condoms: All documents reviewed

Asia Regional HIV/AIDS Project (2007). Evaluation of effective approaches (EAPs) in China (Guangxi and Yunnan).

Asia Regional HIV/AIDS Project (2007). Independent completion report.

Burrows, D. (2006). "Advocacy and coverage of needle exchange programs: results of a comparative study of harm reduction programs in Brazil, Bangladesh, Belarus, Ukraine, Russian Federation, and China." *Cadernos de Saude Publica* 22(4): 871-9.

Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.

Country Coordinating Mechanism People's Republic of China (2007). Proposal form - round 7: China. Beijing: 107.

Hammett, T. M., N. A. Bartlett, et al. (2005). "Law enforcement influences on HIV prevention for injection drug users: Observations from a cross-border project in China and Vietnam." *International Journal of Drug Policy* 16(4): 235-245.

Hong Kong Department of Health (2005/2006). Department of Health Annual Report.

Knoess, J. (2006). HIV/AIDS and Intravenous Drug Use in Asia: A mapping of existing HIV/AIDS and Harm Reduction Programs, Development Oriented Drug Control Program.

Lau, J. T. F., L. Zhang, et al. (2008). "Changes in the prevalence of HIV-related behaviors and perceptions among 1832 injecting drug users in Sichuan, China." *Sexually Transmitted Diseases* 35(4): 325-35.

Mingjian, N., W. J. Ping, et al. Expanded needle and syringe exchange programs in Xinjiang Uyghur Autonomous Region.

Monitoring AIDS Pandemic Network (2005). MAP Report 2005: Drug injection and HIV/AIDS in Asia.

Population Services International (2007). IDU Program - Yunnan Province.

Reid, G., M. L. Devaney, et al. (2008). "Harm reduction programmes in the Asia-Pacific Region." *Drug & Alcohol Review* 27(1): 95-8.

Sullivan, S. G. and Z. Wu (2007). "Rapid scale up of harm reduction in China." *International Journal of Drug Policy* 18(2): 118-28.

UNAIDS (2006). High coverage sites - HIV prevention among injecting drug users in transitional and developing countries. UNAIDS best practice collection. Geneva.

USAID (2007). Understanding service utilization practices of most-at-risk populations accessing a minimum package of HIV/AIDS prevention interventions (DRAFT - Not for circulation).

Wu, Z., S. G. Sullivan, et al. (2007). "Evolution of China's response to HIV/AIDS.[see comment]." *Lancet* 369(9562): 679-90.